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Aortic pulse wave velocity index and mortality in end-stage re- tes mellitus, but also on evaluation of individual risk
nal disease. [1, 2]. Long-term observational studies–based cardiovas-
Background. Aortic pulse wave velocity (PWV) is a strong cular risk profiles, such as Framingham scales [3], haveindependent predictor of overall and cardiovascular mortality
been proposed to improve medical decisions by makingin patients with end-stage renal disease (ESRD). Nevertheless,
risk assessment more quantitative. More recently, in or-because age, blood pressure, heart rate, and gender are strong
determinants of both arterial stiffness and mortality, the indi- der to individualize risk assessment, authors have pro-
vidual relevance of PWV measurements remains controversial. posed an early detection of atherosclerosis (before the
Methods. A cohort of 242 patients with ESRD undergoing occurrence of morbid events) by evaluation of endothe-hemodialysis was studied for a mean ( SD) duration of 78 
lial function, left ventricular mass, microalbuminuria, vas-46 months. At entry, together with standard clinical and bio-
cular calcification, or arterial echographic parameters [4].chemical analyses, PWV was measured using Doppler ultraso-
nography. On the basis of a nomogram established on 469 Several prospective studies have focused on the ability
nonuremic subjects, a theoretical value of PWV was deter- to predict cardiovascular risk through measurements
mined in ESRD patients according to their age, blood pressure,
made on arterial segments, namely carotid intima mediagender, and heart period. The PWV index (measured PWV –
thickness [5-9], carotid incremental modulus of elasticitytheoretical PWV) was then calculated for each individual
ESRD patient. [10], and aortic pulse wave velocity (PWV) [11]. Since epi-
Results. Based on Cox analysis, the PWV index, but neither demiologic and clinical studies have shown that damage
pulse pressure nor cardiac mass, was a strong and independent of large arteries is a major contributory factor to the
predictor of both cardiovascular and overall mortality, together
high cardiovascular morbidity and mortality of patientswith age and time on dialysis before inclusion. Patients with
with end-stage renal disease (ESRD) [10, 12], such apositive (versus negative) PWV index had a twofold adjusted
risk of mortality during the follow-up. Per each 1 meter/second population is particularly appropriate to analyze the im-
PWV index increment, we observed a 34% (crude) and a 14% pact of arterial stiffness on mortality. Indeed, in ESRD
(adjusted) increase in both cardiovascular and overall mortality patients the increased arterial stiffness is associated with
(P  0.02 for all).
acceleration of the arterial aging process, namely dilata-Conclusion. In ESRD patients, the calculation of a PWV
tion and increased wall thickness of major arteries [13].index provides information about cardiovascular and overall
Previously, to identify the impact of aortic stiffening (mea-mortality risk with high predictive power, showing that PWV
measurements provide discriminatory prognostic power over sured from the carotid artery femoral artery PWV) on
and above conventional cardiovascular risk factors. mortality in patients with ESRD, we reported that PWV
was a strong independent predictor of overall and cardio-
vascular mortality in a population of 241 ESRD patients
Recent recommendations for prevention of cardiovas- undergoing hemodialysis [14]. Furthermore, Gue´rin et al
cular disease focus on the levels of reversible risk factors, [15] have recently shown that the loss of aortic PWV sen-
namely dyslipidemia, hypertension, smoking, and diabe- sitivity to blood pressure was predictive of adverse out-
come, indicating that arterial stiffness is not only a risk
factor contributing to the development of cardiovascularKey words: end-stage renal disease, cardiovascular, artery, aortic pulse
wave velocity, mortality. disease but is also a marker of established more ad-
vanced, less reversible arterial changes [15]. Taken to-Received for publication June 11, 2001
gether, these results support the hypothesis that mea-and in revised form February 7, 2002, and October 17, 2002
Accepted for publication January 3, 2003 surement of aortic PWV could then help, not only in
risk assessment strategies, but also in risk reduction strat- 2003 by the International Society of Nephrology
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egies by monitoring those arterial parameters under dif- diac failure, peripheral vascular disease, and cerebrovas-
cular disease. Causes of death (World Health Organiza-ferent drug regimens. Since age, blood pressure, heart
rate, and gender are strong determinants of both arterial tion International Classification of Disease, 9th revision)
were obtained from death certificates, hospital recordstiffness [16] and mortality [3], it is important to calculate
an index that could determine the attributable part of forms, and autopsy data reviewed by the authors. Sudden
death was defined as a witnessed death that occurredarterial stiffness on prediction of mortality, indepen-
dently of these confounders. Such an index would in- within 1 hour after the onset of acute symptoms, with
no evidence that violence or accident played any rolecrease the individual relevance of aortic PWV, in terms
of prognosis. in the fatal outcome. During the follow-up period, we
recorded 91 deaths, including 58 fatal cardiovascularThe aim of this report is to study the relationships
between this PWV index and cardiovascular and overall events. Eighteen deaths were attributed to coronary
heart disease, 15 to cerebrovascular and/or aortic dis-mortality in a population of ESRD patients undergoing
hemodialysis. The results suggest a strong and indepen- ease, 12 to sudden deaths, eight to congestive heart fail-
ure, and five to pulmonary embolism. The 33 fatal non-dent prognostic relevance of this index.
cardiovascular events were 16 deaths due to cancer, nine
to infectious disease, six by withdrawal from dialysis,
METHODS
and two suicides.
Study cohort: ESRD patients
Cardiovascular measurementsThis prospective cohort study was started at the F. H.
Manhe`s Hospital, Fleury-Me´rogis (in the Paris-Ile de The measurements were performed during the 2 weeks
following inclusion, on the morning before the midweekFrance area), in April 1987. Patients were eligible for
entry into the study when (1) they had been on hemodial- hemodialysis. Blood chemistry was measured at baseline
and monthly intervals. Blood pressure was measuredysis at least for 3 months (49  54 months; mean  SD),
and (2) they had had no clinical cardiovascular disease with a mercury sphygmomanometer after 15 minutes of
recumbency. Phases I and V of the Korotkoff sounds wereduring 6 months preceding entry. The cohort reported
in the present work is the same that the cohort reported taken, respectively, as the systolic and diastolic blood
pressure. Five measurements determined at 2-minutein our previous report [14]. However, duration of follow-up
until September 1999 allowed a longer mean follow-up intervals were averaged.
Baseline echocardiography was performed using a Hew-time and the inclusion of one more patient. A total of
242 patients fulfilled the entry criteria. Patients who un- lett-Packard Sonos 100 device (Hewlett-Packard, Ando-
ver, MA, USA) equipped with a 2.25 MHz probe allow-derwent renal transplantation (N  28) and patients
who moved (N 7) were censored at transplantation or ing M mode, two-dimensional, and pulsed Doppler mea-
surements. Measurements were made according to thedeparture to another unit. All but six patients were Cau-
casians. The mean patient follow-up time was 78  46 recommendations of the American Society of Echocardi-
ography [17]. Left ventricular mass was calculated ac-months. Data on mortality were obtained for the entire
cohort. The mean age of the cohort was 52  16 years; cording to the Penn convention, as reported by Devereux
and Reichek [18]. Adequate echocardiographic tracings61% were male; 7% had insulin-treated diabetes melli-
tus; and 48% were treated with different antihyperten- were obtained for 214 subjects. Left ventricular hypertro-
phy (left ventricular mass index 136 g/m2 in men, andsive drugs. A total of 126 patients received recombinant
human erythropoietin at some time during their follow- 110 g/m2 in women) was present in 81% of the ESRD
patients.up. During the follow-up, all patients were dialyzed using
the same unique standardized technique, including syn- Baseline aortic PWV was determined using transcuta-
neous Doppler flow recordings and the foot-to-footthetic membranes hemodialyzers (AN69 and polysulfone)
matched for subject’s body surface area (1.36 to 2.0 m2), method [13, 16]. Two simultaneous Doppler flow tracings
were taken at the aortic arch and the femoral artery inbicarbonate dialysate, and controlled ultrafiltration rate.
The duration of dialysis sessions was tailored (4 to 6 the groin using a nondirectional Doppler unit (SEGA
M842, 10 MHz; Paris, France) with a hand-held probe,hours, three times a week) to achieve a Kt/V1.2 (1.38
0.17). Each subject provided informed consent to partici- and recorded on a Gould 8188 recorder (Gould Elec-
tronique, Ballainvilliers, France) at a speed of 100 to 200pate in the study, which was approved by our Institu-
tional Review Board. mm/seconds. For aortic flow, the transducer was placed
in the suprasternal notch. When a good-quality high-Information compiled from the questionnaire filled
out at inclusion included personal and family histories, frequency signal could not be recorded in this location,
the transducer was placed laterally at the base of the necksmoking habits (127 patients were current or former
smokers), and previous history of cardiovascular disease, and the signal from common carotid artery, opposite to
the site of arteriovenous fistula, was recorded. The timeincluding coronary artery disease, angina pectoris, car-
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delay (t) was measured between the feet of the flow overall mortality. Survival curves were estimated using
the Kaplan-Meier product-limit method and comparedwaves recorded at these different points and was aver-
aged over 10 beats. The distance (D) traveled by the by the Mantel (log-rank) test. Prognostic factors of sur-
vival were identified using the Cox proportional hazardpulse wave was measured over the body surface as the
distance between the two recording sites and when mea- regression model. The assumption of proportional haz-
ards over time and the assumption concerning linearitysured from carotid artery, the distance from the supra-
sternal notch to the carotid artery was subtracted. PWV of continuous covariates were verified. The cohort was
divided into two groups according to whether PWV in-was calculated as PWV  D/t, and expressed in meter/
second. All measurements were done by the same ob- dex was negative (N  86) or positive (N  156). The
cohort was also divided into three groups according toserver (G.M.L.), the intraobserver repeatability of the
aortic PWV measurement was 5.8%  1% [19]. The the PWV index 0.14 m/second in the lower tertile
(N 80), between0.10 and 1.71 m/second in the secondheart period was determined from the three-lead orthog-
onal electrocardiogram (ECG). tertile (N 81), and1.73 m/second in the upper tertile
(N 81). Variables were considered as prognostic when
Determination of PWV index: Nonuremic subjects they were found to be statistically significant (P  0.05)
in the Cox proportional hazards regression models ofIn order to determine multiadjusted PWV cut-off val-
ues, we constructed a nomogram of aortic PWV ac- overall or cardiovascular mortality. The crude and ad-
justed relative risks of experiencing an outcome eventcording to clinical and biologic characteristics (all PWV
measurements made by the same methodology and same during follow-up for the patients with positive PWV in-
dex as compared with the risks of the patients with nega-operator, G.M.L.) in a population of 469 subjects without
ESRD. The choice of this “control” population was made tive PWV index were respectively estimated as the crude
and adjusted hazard ratios. Crude and adjusted hazardin order to obtain mean and range values comparable
to the ESRD population in terms of age, mean blood ratios were calculated as the antilogarithm of the  coef-
ficient of the Cox proportional hazards regression of thepressure, and gender, respectively [50 17 years (range,
14 to 98) versus 51  17 years (range, 13 to 87), 107  outcome events, respectively, without and with all the
prognostic variables, considered as continuous variables16 mm Hg (range, 67 to 156) versus 108  17 mm Hg
(range, 62 to 163), and 1.43 versus 1.39 (one male and two in the models. The 95% CI around the adjusted odds ratio
estimates were obtained with the formula: antilogarithmfemales), all P 0.05]. This population was composed of
outpatients seen in consultation, members of the para- (  1.96 SE), where SE is the standard error of .
To assess the performance of PWV index consideredmedical and medical staffs, and hospitalized patients in
different departments of F. H. Manhe`s Hospital, Fleury- as a diagnostic test, using receiver operating characteris-
tic (ROC) curves, we calculated sensitivities, specificities,Me´rogis, but the Nephrology Department. Information
compiled from the questionnaire filled out at inclusion positive predictive values, and negative predictive values
of PWV index at different cutoff values, in order toincluded personal and family histories, smoking habits,
and previous history of cardiovascular disease, including predict cardiovascular and overall mortality. Optimal
cutoff values of PWV index were defined as the maximi-coronary artery disease, angina pectoris, cardiac failure,
peripheral vascular disease, and cerebrovascular disease. zation of the sum of sensitivity and specificity.
Data are expressed as mean  SD. Student t test wasEach subject provided informed consent to participate
in the study, which was approved by our Institutional used for comparison of normally distributed continuous
variables. Differences in frequency were tested by chi-Review Board.
The equation derived from the multivariate analysis square analysis. Statistical analysis was performed using
NCSS 6.0.21 software. Repeatability and reproducibilitywas then applied to the patients with ESRD in order to
obtain a theoretical PWV value. We finally expressed our of the methods were defined as recommended by the
British Standard Institution [20]. A P value 0.05 wasresults, in the study population of ESRD patients, in
terms of (measured PWV – theoretical PWV), in order to considered significant. All tests were two-sided.
obtain a PWV index adjusted on these four parameters.
RESULTSAnalysis
Multiple regression analysis of PWV in theMultiple regression analysis was performed to assess
populations of 469 patients without ESRD,linear associations between PWV and determinants of
242 patients with ESRD, and in the entire populationclinical, biochemical, and cardiovascular parameters in
the populations of 242 patients with ESRD, 469 patients The independent parameters entering the multivariate
analysis of PWV in both ESRD and non-ESRD popula-without ESRD, and in the entire population.
In the study population of ESRD patients, the out- tions were age, blood pressure, heart period, and gender
(respectively, multiple regression r 2 0.65 and r 2 0.57,come events studied were cardiovascular mortality and
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Table 1. Multiple regression analysis of aortic pulse wave velocity (PWV) in the nonuremic population, the end-stage renal disease (ESRD)
population, and in the entire population
Parameters Parameter Standard
(dependent variable) estimate error Single r 2 P value
Aortic PWV (m/second), nonuremic population (N  469), r 2  0.65
Intercept 2.934 0.625 0.001
Age years 0.0793 0.0038 0.53 0.001
Mean arterial pressure mm Hg 0.0427 0.0039 0.31 0.001
Gender (1 male; 2 female) 0.415 0.121 0.01 0.001
Heart period m/second 0.0014 0.0004 0.02 0.001
Aortic PWV (m/second), ESRD population (N  242), r 2  0.57
Intercept 2.773 1.350 0.04
Age years 0.1189 0.0075 0.39 0.001
Mean arterial pressure mm Hg 0.0616 0.0074 0.08 0.001
Gender (1 male; 2 female) 0.842 0.261 0.01 0.001
Heart period m/second 0.0039 0.0009 0.02 0.001
Aortic PWV (m/second), entire population (N  711), r 2  0.62
Intercept 1.832 0.662 0.006
Age years 0.0917 0.0036 0.44 0.001
Mean arterial pressure mm Hg 0.0449 0.0037 0.18 0.001
Gender (1 male; 2 female) 0.543 0.122 0.01 0.001
Heart period m/second 0.0021 0.0004 0.03 0.001
Code (nonuremic, 1; ESRD, 2) 1.092 0.124 0.06 0.001
P 0.001 for both). Smoking, weight, height, body mass Outcome and prognostic impact of PWV index in
ESRD patientsindex, hemoglobin, white cell count, serum lipids, serum
albumin, serum creatinine, echocardiographic left ven- During the follow-up period, 91 deaths were recorded.
tricular mass, the presence of diabetes mellitus, antihy- According to the Cox analysis, the significant covariates
pertensive therapy, hormone replacement therapy, hy- retained by the model were only age, PWV index, and
pocholesterolemic agents, and previous cardiovascular time on dialysis before inclusion (Table 3). Gender, smok-
events did not reach statistical significance in multivari- ing, blood pressure, heart period, hemoglobin, serum
ate analysis (Table 1). In the multivariate analysis of PWV lipids, serum albumin, left ventricular hypertrophy, para-
in the entire population, a code effect (nonuremic  1, thyroid hormone, and previous cardiovascular events did
ESRD  2) accounted for 5.3% of total variance. not reach statistical significance in multivariate analysis.
The following equation, derived from the multivariate After adjustments for the prognostic variables (age and
analysis, was then applied to the patients with ESRD in time on dialysis before inclusion), PWV index was a strong
order to obtain a theoretical PWV value: predictor of mortality (Table 4). Compared to patients
with negative PWV index, patients with positive PWVTheoretical PWV (m/s)  0.0793
index had a twofold adjusted risk of overall mortality
	 age (years) 
 0.0427 (95% CI, 1.11 to 3.54). For each PWV index’s increase
of 1 m/second in our study population, adjusted overall	 mean blood pressure (mm Hg)
mortality relative risk was 1.14 (95% CI, 1.05 to 1.24).
 0.0014 	 heart period (ms) During the follow-up period, 58 cardiovascular deaths
occurred. According to the Cox analysis, the significant 0.415 	 gender
covariates entering the model were age, time on dialysis
(male  1, female  2) 
 2.934. before inclusion, PWV index, and hemoglobin (Table 3).
Gender, smoking, blood pressure, heart period, serum
ESRD patient characteristics lipids, serum albumin, left ventricular hypertrophy, para-
The characteristics of the cohort at the time of inclu- thyroid hormone, and previous cardiovascular events did
sion, according to the level of PWV index (negative or not reach statistical significance in multivariate analysis.
positive), are shown in Table 2. Age at inclusion, age After adjustments for all the prognostic variables, PWV
at the initiation of dialysis, prevalence of diabetes and index was again a strong predictor of cardiovascular mor-
previous cardiovascular events, tobacco lifelong dose, tality (Table 4). Compared to patients with negative PWV
systolic blood pressure, pulse pressure, and PWV were index, patients with positive PWV index had a twofold
significantly lower in the group of patients with negative adjusted risk of overall mortality (95% CI, 0.93 to 4.10).
PWV index as compared with the patients with positive For each PWV index’s increase of 1 m/second in our study
population, the adjusted relative risk of overall mortalityPWV index (P  0.01 for all).
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Table 2. Characteristics of patients at inclusion according to the level of the pulse wave velocity (PWV) index (negative or positive)
Negative PWV index Positive PWV index
Parameters (N  86) (N  156) P value
Age years 4715 5517 0.001
Gender M/F 54/32 96/60 —
Type 1 diabetes number 3 13 —
Time on dialysis before inclusion months 5153 4854 —
Age at initiation of dialysis years 4316 5117 0.001
Previous cardiovascular events number 6 55 0.001
Anti-HTA drugs at inclusion number 40 75 —
Life time dose of tobacco pack-years 57 1117 0.002
Systolic blood pressure mm Hg 14927 16128 0.001
Diastolic blood pressure mm Hg 8616 8416 —
Mean blood pressure mm Hg 10718 11018 —
Pulse pressure mm Hg 6319 7722 0.001
Heart rate bpm 7311 7512 —
Hemoglobin mmol/L 5.61.1 5.81.2 —
Total cholesterol mmol/L 5.31.2 5.21.1 —
HDL cholesterol mmol/L 1.10.4 1.10.5 —
LDL cholesterol mmol/L 3.51.1 3.41.0 —
Triglycerides mmol/L 1.81.1 1.81.0 —
Total/HDL cholesterol ratio 5.32.2 5.11.9 —
Parathyroid hormone pg/mL 210207 250258 —
Left ventricular mass index g/m2 16546 17249 —
Measured PWV m/second 8.51.4 12.52.9 0.001
Theoretical PWV m/second 9.41.3 10.21.5 0.001
V index m/second 0.90.6 2.42.0 0.001
Abbreviations are: HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Table 3. Proportional hazards regression analysis of cardiovascular and all-cause mortality
Regression Standard
Parameters coefficient error z value Pseudo R 2 P value
Cardiovascular mortality (yes, no)a
Age years 0.078 0.013 6.10 0.19 0.001
Time on dialysis before inclusion months 0.006 0.002 2.87 0.05 0.004
PWV index m/second 0.130 0.052 2.50 0.04 0.012
Hemoglobin mmol/L 0.251 0.114 2.19 0.03 0.028
All-cause mortality (yes, no)b
Age years 0.075 0.010 7.50 0.24 0.001
PWV index m/second 0.132 0.043 3.10 0.05 0.002
Time on dialysis before inclusion months 0.004 0.002 2.37 0.03 0.018
PWV is pulse wave velocity.
a Model pseudo R 2  0.35; model chi-square  87; model probability P  0.0001
b Model pseudo R 2  0.40; model chi-square  121; model probability P  0.0001
Table 4. Hazard ratios (HR) of mortality (cardiovascular and all-cause) according to pulse wave velocity (PWV) index
and the level of pulse pressure (PP) at inclusion
Cardiovascular mortality
No. of Deaths number Crude hazards ratio Adjusted hazards ratio
Prognostic variable subjects (%) (95% CI) (95% CI)
PWV index m/second 242 58 (24)
Negative PWV indexa 86 9 (10) 1 1
Positive PWV index 156 49 (31) 3.62 (1.77–7.38) 1.96 (0.93–4.10)
Per 1 m/seconds PWV index increment 1.34 (1.23–1.47) 1.14 (1.03–1.26)
Per 10 mm Hg pulse pressure increment 1.25 (1.14–1.36) 1.04 (0.92–1.18)
All-cause mortality
PWV index m/second 242 91 (38)
Negative PWV indexa 86 15 (17) 1 1
Positive PWV index 156 76 (49) 3.45 (1.98–6.01) 1.98 (1.11–3.54)
Per 1 m/seconds PWV index increment 1.34 (1.24–1.44) 1.14 (1.05–1.24)
Per 10 mm Hg pulse pressure increment 1.22 (1.13–1.31) 0.98 (0.89–1.08)
Adjustments were made on independent determinants in proportional hazards regression analysis.
a The patients in this category served as the reference group
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Fig. 1. Probabilities of event-free survival (cardiovascular mortality) Fig. 2. Probabilities of overall survival in the study population ac-
cording to the level of pulse wave velocity (PWV) index (negativein the study population according to the level of pulse wave velocity
(PWV) index (negative versus positive and division in tertiles). Compar- versus positive and division in tertiles). Comparisons between survival
curves were highly significant (respectively, chi square  22.6 and 37.1;isons between survival curves were highly significant (respectively, chi
square  14.9 and 28.3; P  0.001 for both). P  0.001 for both).
DISCUSSIONwas 1.14 (95% CI, 1.03 to 1.26). It is important to note
that, after adjustment on age, PWV index (or PWV abso- The salient finding of this study was that, in a popula-
lute values) did not enter the prediction model of noncar- tion of ESRD patients undergoing hemodialysis, PWV
diovascular mortality (33 deaths). index was a strong predictor of cardiovascular and over-
While each increase of 10 mm Hg in pulse pressure at all mortality with high performance values.
inclusion was significantly associated with cardiovascular PWV measurement offers a simple, reproducible, indi-
and overall mortality in crude analysis (respectively,
25 rect, and noninvasive evaluation of regional arterial stiff-
and
22% risks, P 0.001 for both), multiadjusted pulse ness [16, 21–24]. The PWV determined from foot-to-foot
pressure odds ratios of both cardiovascular and overall transit time in the aorta eliminates the influence of wave
mortality were not statistically different from 1 (Table 4). reflections and is close to the characteristic PWV deter-
Figures 1 and 2 show the probabilities of cardiovascu- mined from phase velocities [16]. The critical factors are
lar and overall survival as a function of PWV index values. the precise measurements of this transit time and the
Comparisons between survival curves were highly sig- length of the vascular segments. Transcutaneous deter-
nificant. mination of the vessel length is an approximation that
Optimal cutoff value of PWV index in order to predict might underestimate the vascular length, an error that
cardiovascular mortality was 1.63 m/second with the fol- might arise, especially in elderly patients with tortuous
lowing performance: 62% sensitivity, 74% specificity, aorta. Despite these limitations, measurement of PWV
43% positive predictive value, and 86% negative pre- is strongly correlated to direct measurements of arterial
dictive value (area under ROC curve  0.72  0.12) distensibility and can be considered a good surrogate
(Fig. 3). Optimal cutoff value of PWV index in order to to evaluation of arterial stiffness by phase-locked echo-
predict overall mortality was 0.68 m/second with follow- tracking systems [13].
ing performance: 73% sensitivity, 65% specificity, 55% Aortic PWV increases with age and blood pressure
positive predictive value and 80% negative predictive and must be interpreted accordingly. Studies in ESRD
patients have shown that arterial stiffness is enhancedvalue (area under ROC curve  0.75  0.10) (Fig. 3).
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garding the antihypertensive drug effect on PWV in this
population.
In the multivariate analysis of PWV in the nonuremic
population the model was built with mean blood pressure
because according to the Laplace law, it is the steady
component of blood pressure, namely mean blood pres-
sure, which is the major determinant of arterial wall
stress and then pressure-induced changes in steady arte-
rial distensibility (wall stress  mean blood pressure 	
arterial diameter/wall thickness) [16]. On the other hand,
the level of pulse pressure is determined by ventricular
ejection and mainly wave reflection and arterial stiffness
itself [16]. The level of pulse pressure was higher in the
ESRD population than in the nonuremic population, and
within the ESRD population, the level of pulse pressure
significantly differs between the patients with negative
versus positive PWV index. The most obvious conse-
quences of arterial stiffening are increased pulsatile
blood pressure due to higher systolic and lower diastolic
blood pressure, thereby causing increased left ventricular
afterload and altering coronary perfusion [25, 26]. The
principal outcomes of these changes are left ventricular
hypertrophy, aggravation of coronary ischemia, and in-
creased fatigue of arterial wall tissues. Higher systolic
blood pressure and pulse pressure, lower diastolic blood
pressure, and left ventricular hypertrophy have been
identified as independent factors of cardiovascular mor-
bidity and mortality in the general population [27–38]
as well as in ESRD patients [25, 26, 39]. In the present
study, pulse pressure at inclusion was a strong predictor
of cardiovascular and overall mortality, but this parame-Fig. 3. Receiving operating characteristic (ROC) curves: pulse wave
velocity (PWV) index in the detection of cardiovascular and overall ter (just like cardiac hypertrophy) did not enter the mul-
mortality. Area under curves, respectively, 0.72  0.11 and 0.75 0.10. tivariate Cox analysis partly because strong intercorrela-
tion with PWV index (r  0.40, P  0.001) and age (r 
0.36, P  0.001). This finding is of major importance,
suggesting that the numerous reported age-adjusted rela-independently of age and blood pressure [13], making
these patients an appropriate test population to analyze tionships between pulse pressure, cardiac hypertrophy,
and cardiovascular risk [29-37] could be mediated bythe impact of arterial stiffness on mortality. In the pres-
ent study, by using the PWV nomogram obtained in a increased arterial stiffness.
Whether enhanced arterial stiffness is a risk factor con-nonuremic population with the same age, gender, and
mean blood pressure, calculation of the PWV index (mea- tributing to the development of cardiovascular disease
or is a marker of established cardiovascular disease is asured PWV theoretical PWV) should give a value that
is independent of age, blood pressure, gender, and heart matter of debate. A study in Chinese and Australians [40]
has suggested that morphologic and structural alterationsrate. The differences in age and systolic blood pressure
between patients with negative versus positive PWV in- of the aorta may be influenced by both environmental
and mostly genetic factors. A role for genetic factors wasdex probably reflects the heavier weight of these two pa-
rameters on arterial alterations in ESRD patients; aging also supported by the data from Benetos et al [41] who
observed that the angiotensin II type 1 receptor gene canand systolic hypertension acting as even more deleteri-
ous vascular risk factors in ESRD populations than in influence aortic stiffness. These examples suggest that
changes of biomechanical properties of major arteriespopulations with normal renal function. Since the pres-
ence of pharmacologic drug therapy did not significantly may precede the development of clinically overt disease.
It is important to note that calculation of an index isdiffer between the patients with negative versus positive
PWV index, and since hypertension treatment decision always limited by the variability or uncertainty in esti-
mates. Furthermore, the theoretical PWV index shouldwas clinically based and not randomly allocated, it is not
methodologically possible to propose an hypothesis re- have been different based on another control group. The
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and media thickness as a risk factor for myocardial infarction andpresent analysis does not give much additional evidence
stroke in older adults. N Engl J Med 340:14–22, 1999
of a relationship between arterial stiffness and mortality, 10. Blacher J, Pannier B, Guerin A, et al: Impact of carotid stiffness
on cardiovascular and all-cause mortality in end-stage renal failure.but tries to make the PWV measurement more individu-
Hypertension 32:570–574, 1998ally relevant.
11. Lehmann ED: Pulse wave velocity as a marker of vascular disease.
Lancet 348:741, 1996
12. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated
CONCLUSION atherosclerosis in prolonged maintenance hemodialysis. N Engl J
Med 290:697–701, 1974The present study has shown, in a cohort of ESRD
13. London GM, Gue´rin AP, Marchais SJ, et al: Cardiac and arterial
subjects undergoing hemodialysis, that increased PWV interactions in end-stage renal disease. Kidney Int 50:600–608, 1996
14. Blacher J, Gue´rin A, Pannier B, et al: Impact of aortic stiffnessindex was a strong predictor of cardiovascular and over-
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